311 related articles for article (PubMed ID: 16773180)
21. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.
Dutta T; Sharma H; Kumar L; Dinda AK; Kumar S; Bhatla N; Singh N
Cancer Chemother Pharmacol; 2005 Oct; 56(4):427-35. PubMed ID: 15906030
[TBL] [Abstract][Full Text] [Related]
23. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
24. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ
Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173
[TBL] [Abstract][Full Text] [Related]
25. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
26. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer.
Taniwaki M; Daigo Y; Ishikawa N; Takano A; Tsunoda T; Yasui W; Inai K; Kohno N; Nakamura Y
Int J Oncol; 2006 Sep; 29(3):567-75. PubMed ID: 16865272
[TBL] [Abstract][Full Text] [Related]
28. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.
Felix RS; Colleoni GW; Caballero OL; Yamamoto M; Almeida MS; Andrade VC; Chauffaille Mde L; Silva WA; Begnami MD; Soares FA; Simpson AJ; Zago MA; Vettore AL
Cancer Lett; 2009 Jun; 278(1):41-8. PubMed ID: 19171422
[TBL] [Abstract][Full Text] [Related]
29. Adhesion, migration, transcriptional, interferon-inducible, and other signaling molecules newly implicated in cancer susceptibility and resistance of JB6 cells by cDNA microarray analyses.
Samuel S; Bernstein LR
Mol Carcinog; 2004 Jan; 39(1):34-60. PubMed ID: 14694446
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
31. Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer.
Takano M; Fujii K; Kita T; Kikuchi Y; Uchida K
Oncol Rep; 2004 Dec; 12(6):1177-82. PubMed ID: 15547734
[TBL] [Abstract][Full Text] [Related]
32. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
33. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
34. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
35. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
[TBL] [Abstract][Full Text] [Related]
36. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
Soto A; DelRaso NJ; Schlager JJ; Chan VT
Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
[TBL] [Abstract][Full Text] [Related]
37. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
[TBL] [Abstract][Full Text] [Related]
38. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R
Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
[TBL] [Abstract][Full Text] [Related]
39. D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats.
Davidson ME; Kerepesi LA; Soto A; Chan VT
Arch Toxicol; 2009 Aug; 83(8):747-62. PubMed ID: 19212759
[TBL] [Abstract][Full Text] [Related]
40. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer.
Zhao YP; Chen G; Feng B; Zhang TP; Ma EL; Wu YD
Chin Med J (Engl); 2007 Oct; 120(20):1743-52. PubMed ID: 18028764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
